Firebrick appoints Dr Richard Treagus as director

  • Dr Richard Treagus is an important appointment to the FRE board
  • Dr Treagus is a medical doctor with extensive ASX experience and a valuable background in pharmaceutical sales and marketing
  • Most recently, Dr Treagus was Executive Chairman of Neuren Pharmaceuticals (ASX: NEU), a successful Australian biotech company

Firebrick Pharma is pleased to announce the appointment of Dr Richard Treagus as a non-executive director on the Firebrick board of directors, with effect from 1 June 2022.

“We have had ongoing discussions with Richard about Firebrick since the Company was founded and are excited that he has agreed to join our board,” said Firebrick Executive Chairman, Dr Peter Molloy. “Richard brings valuable insights, not only as a medical doctor and very experienced director, but as someone with expertise in OTC pharmaceutical marketing.”

Dr Treagus was previously Commercial Director for Aspen Pharmacare in South Africa, responsible for sales and marketing of pharmacy and consumer products. More recently, from 2006 to 2012, he was CEO of Acrux Limited (ASX:ACR), which grew 10-fold in value during his tenure and from 2013 to 2020, he was Executive Chairman of Neuren Pharmaceuticals Limited (ASX:NEU), which grew 6-fold in value during his tenure.

Dr Treagus is also Executive Chairman and Founder of BTC Health (ASX:BTC).

Dr Treagus said: “Firebrick is a great example of a late-stage innovative Australian pharmaceutical company, developing a novel medical treatment for a widespread and costly medical condition. I look forward to supporting the Firebrick team as they move Nasodine through Phase 3 and towards marketing approval in the major global markets.”

In the Firebrick prospectus (p. 42), the Company indicated that after listing it intended to appoint an additional independent non-executive director with skills and expertise that complement the members of the existing Board. From 1 June, the Firebrick board will comprise four directors: The founders, Dr Stephen Goodall and Dr Peter Molloy, plus two non-executive directors, with Dr Treagus joining Dr Phyllis Gardner as the second non-executive director. Dr Gardner is a Professor of Medicine at Stanford University and is also on the Board of Fellows of Harvard Medical School.